RXI Pharma (NASDAQ: RXII) announced that their third Phase 2a study (RXI-109-1402) with RXI-109, for the reduction of recurrence of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE